Collaboration is key. At Phazemos, we excel at fostering partnerships that drive innovation and growth. This blog will examine how two members of the Phazemos network effectively leveraged our services to achieve their distinct objectives.

We know how essential it is to meet your deadlines and stay within budget—without sacrificing quality. We’ve built a trusted ecosystem that connects biotech, pharma, and med device companies with a network of top-tier, small to mid-sized providers, offering expert solutions at a fraction of the cost of traditional CROs.

If you're a therapeutic development service provider who feels like selling takes you away from delivering exceptional work, you're not alone. For many small business owners, selling can feel like a necessary, but unwanted, distraction. Dive into an alternative that will let you do more of what you want to.

Grow your sales pipeline without growing your team. Learn about our proven, low-cost formula for smarter for small companies in the clinical development space. Learn how our Pipeline Development Program to kickstart your growth journey

Small biotech companies often face the challenge of integrating sophisticated bioinformatics solutions into their operations. Here's how we help specialized bioinformatics find its place in serving these companies.

Phazemos was approached by a member exploring a potential exit strategy. The prospective SMO buyer initially showed interest in acquiring, however, during preliminary discussions, it became clear that their commitment to the acquisition was tenuous at best. What truly piqued the SMO’s interest was leveraging the consultancy services of our member for a strategic technology development project.

A promising biotech company reached out to Phazemos with a goal to raise a $3 million seed round. They needed a partner who could not only provide the necessary capital but also add value through industry expertise and strategic connections. Our task was clear, and we were ready to leverage our flexible Match Program to make it happen.

Successfully expanding into international markets can be a complex endeavor. For Chinese biotech companies that have completed Phase I trials and are eager to broaden their research into the U.S., the path forward is filled with both opportunity and regulatory intricacy. At Phazemos, we understand the unique challenges faced by these firms and provide expert guidance to help them establish a solid foothold in the U.S. market.

A promising startup approached Phazemos seeking assistance in raising a $250,000 pre-seed round. They needed targeted support to identify the right investor capable of kickstarting their ambitious growth plan. Read how we helped.